Praluent (Alirocumab)

Description

Effective Treatment for High Cholesterol and Cardiovascular Risk

Praluent (Alirocumab) is a monoclonal antibody used to lower LDL cholesterol in patients with hyperlipidemia, especially those at high risk for cardiovascular diseases. It is primarily used as an adjunct to diet and statin therapy for patients with familial hypercholesterolemia or those unable to tolerate statins.

Unlike traditional cholesterol-lowering medications, Praluent works by inhibiting PCSK9, a protein that interferes with the liver’s ability to clear LDL cholesterol. By blocking PCSK9, Praluent increases the liver’s capacity to clear LDL-C from the bloodstream, effectively lowering cholesterol levels and reducing the risk of heart attacks and strokes.

Why Choose Praluent?

• Proven Efficacy: Offers significant LDL-C reduction and proven results in reducing cardiovascular risks.

• No Statin Required: Effective for patients who cannot tolerate statins or need extra cholesterol-lowering therapy.

• Convenient Administration: Administered as a subcutaneous injection every two weeks for flexible treatment scheduling.

• Proven Safety: Supported by clinical data showing safety and efficacy in lowering cholesterol.

Common Usage & Dosage

Praluent is typically administered as a subcutaneous injection every two weeks. The dosage is available in 75 mg/ml and 150 mg/ml formulations, with the appropriate dosage being determined by your healthcare provider based on your condition.